Clinical Medicine Equipment With Solution For Access To Investigational Medicines Applications
-
based in CANADA
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted ...
-
based in CANADA
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory pair such as PD-1/PD-L1. Therapeutics utilizing ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you